Kardiovaskuläres Risiko unter Androgendeprivationstherapie zur Behandlung des hormonabhängigen Prostatakarzinoms
Authors:
- 15 April 2016
- journal article
- research article
- Published by Springer Nature in Herz
- Vol. 41 (8) , 697-705
Abstract
Several studies have indicated that reduction of testosterone levels in patients with prostate cancer undergoing androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists can be associated with an increased risk of cardiovascular events. The GnRH antagonists have a different mode of action compared with GnRH agonists and may be preferred in ADT for patients with cardiovascular disease.This review article discusses potential mechanisms underlying the development of cardiovascular events associated with ADT when using GnRH agonists and explains the differences in mode of action between GnRH agonists and GnRH antagonists. Additionally, relevant studies are presented and practical recommendations for the clinical practice are provided.A literature search was performed. Full publications and abstracts published in the last 10 years up to September 2015 were considered to be eligible.The GnRH antagonists were associated with a decreased risk of cardiovascular events compared with GnRH agonists in prostate cancer patients undergoing ADT and particularly in patients with cardiovascular risk factors or a history of cardiovascular disease. This decrease may be due to the different mode of action of GnRH antagonists compared with GnRH agonists.Prostate cancer patients with either cardiovascular disease or an increased risk of experiencing a cardiovascular event undergoing ADT should be preferentially treated with GnRH antagonists.Keywords
This publication has 54 references indexed in Scilit:
- Testosterone and the Cardiovascular System: A Comprehensive Review of the Basic Science LiteratureJournal of the American Heart Association, 2013
- The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversyCritical Reviews in Oncology/Hematology, 2013
- Androgen-Deprivation Therapy for Nonmetastatic Prostate Cancer Is Associated With an Increased Risk of Peripheral Arterial Disease and Venous ThromboembolismEuropean Urology, 2012
- The Heart: A Novel Gonadotrophin-Releasing Hormone TargetJournal of Neuroendocrinology, 2011
- Effects of Gonadotrophin‐Releasing Hormone Outside the Hypothalamic‐Pituitary‐Reproductive AxisJournal of Neuroendocrinology, 2009
- Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31Journal of Clinical Oncology, 2009
- Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancerCancer, 2008
- Testosterone protects rat hearts against ischaemic insults by enhancing the effects of α 1 ‐adrenoceptor stimulationBritish Journal of Pharmacology, 2008
- Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate CancerUrology, 2008
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006